Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?



Code Company Date Close Change Indicator Value Signal

Trading Performance

Average Directional Index



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 3 145.3 0.33% 0.50% 292.3% -10.8% 270.6%
SHORT 2 96.5 0.50% 1.00% 6.9% -16.9% -10.0%


Technical Analysis

Opthea (OPT.AX)



Last Signal:


Trading: HOLD @ $2.64
Signal Strength: MEDIUM

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.

Opthea (ASX:OPT) has confirmed a very strong trend is present. Opthea has an ATR(14) of 0.222, a DX of 68.35 & an ADX(14) of 50.89

The Average Directional Index (ADX) Minus Directional Indicator (-DI) and Plus Directional Indicator (+DI) represent a group of directional movement indicators that form a trading system developed by Welles Wilder.

Calculation: Average Directional Movement Index (ADX):
Trend Strength ;
1) 0-25 = Absent or Weak Trend;
2) 25-50 = Strong Trend;
3) 50-75 = Very Strong Trend;
4) 75-100 Extremely Strong Trend;


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:

Average Directional Index

Company Close Change(%) Volume Value Signal
GGG Greenland Minerals 0.13 8.7 3,210,796 31.28 BULLISH
IMD Imdex 1.3 7.9 4,121,418 26.97 BULLISH
YAL Yancoal Australia 3.44 6.5 33,478 29.68 BULLISH
ISX Isignthis 1.02 5.7 1,816,615 44.58 BULLISH
MDC Mcconnell Dowell Corporation 0.47 5.7 173,687 39.47 BULLISH
BRN Brainchip Holdings 0.05 4.5 1,890,659 29.88 BULLISH
PME Pro Medicus 27.14 4.5 364,894 26.66 BULLISH
COH Cochlear 217.79 4 213,638 29.39 BULLISH
KAR Karoon Gas Australia 1.32 4 1,321,398 35.69 BULLISH
NEA Nearmap 3.04 3.8 3,707,997 26.05 BULLISH